LY 171883, a CysLT1 Receptor (leukotriene D4) antagonist, has been shown to displace oleic acid (sc-200797) binding to fatty-acid-binding protein (FABP) which may be involved in fatty acid metabolism. Studies suggest that this compound contains structural similarity to fatty acids, hence the ability to bind to FABPs. Additional data suggests that LY 171883 causes membrane hyperpolarization and reduces firing rate of action potentials in neuroblastoma cells in vitro. LY 171883 is an inhibitor of PDE and an activator of PPAR α and PPAR γ.
1. Fleisch, J.H., et al. 1985. J. Pharmacol. Exp. Ther. 233: 148-157. PMID: 3981452
2. Aharony, D., et al. 1987. J. Pharmacol. Exp. Ther. 243: 921-926. PMID: 2826761
3. Cannon, J.R. and Eacho, P.I. 1991. Biochem. J. 280: 387-391. PMID: 1747111
4. Li, P.C., et al. 2002. J. Cell. Physiol. 192: 188-199. PMID: 12115725
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.